GRAIL Inc (GRAL) Stock Forecast & Price Target

GRAIL is viewed favorably because Galleri sits at the center of a large, underpenetrated multi-cancer screening market, with an annual testing opportunity that could exceed 100M in the U.S. and 300M in major global markets. Its clinical package is compelling, with PATHFINDER 2 showing 60% positive predictive value, 99.6% specificity, and 91.9% cancer signal origin accuracy, while NHS-Galleri showed a 14% reduction in Stage IV cancers. The outlook is further strengthened by the prospect of FDA approval in late 2026 or 1H27, a formal Medicare reimbursement pathway after the February 2026 legislation, and expanding adoption as payer coverage, guidelines, and clinical workflows develop.

GRAIL is a development-stage diagnostics company facing fundamental uncertainty because its multi-cancer early detection platform still depends on lengthy, costly clinical studies and an FDA process that has never approved an MCED test, leaving approval, coverage, and reimbursement far from certain. Despite private reimbursement from multiple U.S. payers, Galleri lacks broad government coverage such as Medicare, while significant net losses, heavy commercialization spending, and reliance on single-source suppliers increase cash burn and execution risk. Even under bullish volume assumptions, the stock faces a structurally limited self-pay market, weak conversion, and a delayed reimbursement path, all of which suggest sales growth could undershoot expectations and margins could be pressured when royalties resume in 2027.